TLR4
ENSG00000136869
Target class
Membrane receptor
Chromosome
9
Approved drugs
0
Clinical candidates (approved and in development)
2
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- Yes
- Target name
- TLR4
- Gene name
- Toll like receptor 4
- Gene symbol
- TLR4
- Protein name
- Toll-like receptor 4 (hToll) (CD antigen CD284)
- hToll
- CD284
- TLR-4
- ARMD10
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Toll like receptors
- Target class
- Membrane receptor
- Target type
- Human gene
- Tissues expressed in
- 52
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 40.49
- Tissue specificity (Gini)
- 0.435
- Tissue specificity (tau)
- 0.794
- KEGG gene identifiers
- hsa:7099
- Protein interaction confidence
- 0.85544
- Protein interaction partners
- 218
- R-HSA-1236974
- R-HSA-140534
- R-HSA-166016
- R-HSA-166058
- R-HSA-166166
- R-HSA-2562578
- R-HSA-5602498
- R-HSA-5603041
- R-HSA-5686938
- R-HSA-936964
- R-HSA-937041
- R-HSA-937072
- R-HSA-9707616
- R-HSA-975163
- R-HSA-9820960
- R-HSA-9824878
- R-HSA-9833110
- R-HSA-9918481
- End position
- 117724735
- Start position
- 117704175
- Chromosome
- 9
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein . Early endosome . Cell projection, ruffle . Note=Upon complex formation with CD36 and TLR6, internalized through dynamin-dependent endocytosis (PubMed:20037584). Colocalizes with RFTN1 at cell membrane and then together with RFTN1 moves to endosomes, upon lipopolysaccharide stimulation. Co-localizes with ZG16B/PAUF at the cell membrane of pancreatic cancer cells (PubMed:36232715). .
- Plasma membrane
- PubMed 11274165
- PubMed 17098818
- PubMed 20037584
- PubMed 21393102
- PubMed 27022195
- PubMed 36232715
- PubMed 36945827
- PubMed 38670073
- PubMed 9237759
- Tissue specificity (tau)
- 0.794019
- Expression inequality (Gini)
- 0.434607
Expression in transcripts per million
- Spleen
- 40.49
- Whole Blood
- 40.08
- Adipose - Visceral (Omentum)
- 27.58
- Lung
- 23.4
- Adipose - Subcutaneous
- 23.25
Expression in transcripts per million
- Spleen40.49
- Whole Blood40.08
- Adipose - Visceral (Omentum)27.58
- Lung23.4
- Adipose - Subcutaneous23.25
- Cells - Cultured fibroblasts21.55
- Breast - Mammary Tissue19.23
- Artery - Aorta17.34
- Artery - Coronary15.84
- Thyroid11.93
- Nerve - Tibial10.72
- Adrenal Gland9.99
- Minor Salivary Gland9.51
- Cervix - Endocervix8.38
- Uterus8.16
- Esophagus - Gastroesophageal Junction8.03
- Bladder7.93
- Fallopian Tube7.89
- Small Intestine - Terminal Ileum7.57
- Ovary7.52
- Brain - Caudate (basal ganglia)7.41
- Esophagus - Muscularis7.4
- Artery - Tibial7.22
- Prostate6.89
- Kidney - Medulla6.76
And 29 more, listed on the interactive page.
- GO:0002224
- GO:0002755
- GO:0006909
- GO:0006954
- GO:0006955
- GO:0010628
- GO:0031663
- GO:0032496
- GO:0032497
- GO:0032722
- GO:0032731
- GO:0032735
- GO:0032755
- GO:0032757
- GO:0032760
- GO:0034142
- GO:0042116
- GO:0042742
- GO:0043123
- GO:0045087
- GO:0045944
- GO:0050729
- GO:0050829
- GO:0071222
- GO:0071260
And 7 more, listed on the interactive page.
- GO:0001891
- GO:0005737
- GO:0005886
- GO:0009897
- GO:0009986
- GO:0010008
- GO:0043235
- GO:0046696
- GO:0048471
- GO:0001530
- GO:0001540
- GO:0001875
- GO:0004888
- GO:0005102
- GO:0005515
- GO:0038023
- GO:0042802
- GO:0046982
Related records
Trials (16)
- A Phase I, 2-part (Part 1 Being a Single Dose Escalation and Part 2, a Parallel Group) Study of Toll-like Receptor (TLR4) Agonist (GSK1795091) in Healthy Subjects
- A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis
- A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors
- A-TANGO Phase 2 Study
- ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis
- Efficacy & Safety of Resatorvid in Adults With Severe Sepsis
- Efficacy and Safety of Resatorvid in Patients With Sepsis-induced Cardiovascular and Respiratory Failure
- JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
- JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
- Mechanisms of Pain Hypersensitivity in a Human Skin Inflammation Model
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
- Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors
- Study of an Anti-TLR4 mAb in Rheumatoid Arthritis
- TAK-242 in Patients With Acute Alcoholic Hepatitis
- The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects
- The Role of TLR4 on Lipid-induced Insulin Resistance
Drugs (5)
- Eritoran Toll-like receptor 4/MD-2 antagonist
- Eritoran tetrasodium Toll-like receptor 4/MD-2 antagonist
- GSK-1795091
- Paridiprubart
- Resatorvid Toll-like receptor 4 inhibitor